Tina Oliver, DPM
Podiatrist · Houston, TXNPI 1467470245
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $29,047 of the $41,902 with a category attached, or 69.3%. Smith+Nephew accounts for 97.7% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2019 at $35,479 and has fallen 99.5% since, to $187 in 2025. Among podiatrist clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 171 payments — averaging $245.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Smith+Nephew$41K
- Acera Surgical, Inc.$191
- Stryker$130
- AbbVie$126
- Organogenesis Inc.$105
- Musculoskeletal Transplant Foundation Inc.$78
- plus $341 from 11 others
What the payments were for
- Speaking & faculty fees$29,04769%
- Travel & lodging$9,25422%
- Food & beverage$3,5919%
- Education$100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Smith+Nephew | 141 | $40,930 |
| Acera Surgical, Inc. | 1 | $191 |
| Stryker(2 entities) | 4 | $130 |
| AbbVie(2 entities) | 3 | $126 |
| Organogenesis Inc. | 3 | $105 |
| Musculoskeletal Transplant Foundation Inc. | 1 | $78 |
| Treace Medical Concepts, Inc. | 3 | $63 |
| Melinta Therapeutics, LLC | 3 | $51 |
| ETS Wound Care LLC | 2 | $44 |
| Scilex Pharmaceuticals Inc. | 1 | $42 |
| Convatec Inc. | 2 | $33 |
| Kerecis Limited | 2 | $26 |
| Amgen | 1 | $24 |
| Nevro Corp. | 1 | $17 |
| Baudax Bio Inc. | 1 | $16 |
| Aroa Biosurgery Incorporated | 1 | $15 |
| Trimed, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Santyl$32,709
- REGRANEX$24,363
- Oasis$20,154
- Grafix$796
- VERSAJET II$796
- Renasys$689
- PICO$689
- Restrata Wound Matrix$191
- Stravix$107
- STRAVIX PL$107
- GRAFIX PL$107
How this compares
$41,902 in reported general payments places this provider in the 90th percentile of 470 podiatrist providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SantylCollagenase Clostridium Hist. | 18 | $10,130 |
| Ammonium Lactate | 20 | $462 |
| Ketoconazole | 25 | $323 |
| Mupirocin | 28 | $167 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Smith+NephewSantyl | $40,930 | $10,13018 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 470 podiatrist providers in Texas.
Other podiatrist in Houston
- Gary LepowHouston$1M
- Andrew SchneiderHouston$150K
- Randall BeckmanHouston$103K
- Jason ArmstrongHouston$91K
- Jerry MilesHouston$58K
- Lawrence MactavishHouston$41K
- Roberto de Los SantosHouston$33K
- Randal LepowHouston$33K
- Ava WashkoHouston$19K
- Jeffrey RossHouston$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.